Differential gene expression profiling of human epidermal growth factor receptor 2-overexpressing mammary tumor

Acta Biochimica et Biophysica Sinica

Volumn 40, Issue 5, 2008, Pages 397-405

  Wang, Yan ^a   Peng, Haining ^a   Zhong, Yingli ^a   Li, Daiqiang ^b   Tang, Mi ^b   Ding, Xiaofeng ^a   Zhang, Jian ^a,c  

^a HUNAN NORMAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

HER2; Mammary tumor; Suppression subtractive hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR PROTEIN;

ANIMAL; ARTICLE; CELL CULTURE; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MOUSE; UPREGULATION;

ANIMALS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 43949085720     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2008.00419.x     Document Type: Article

References (29)

1. Dendukuri N, Khetani K, McIsaac M, Brophy J. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007, 176 : 1429 1434.
2. Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer 2006, 13 : 39 49.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235 : 177 182.
4. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988, 319 : 1239 1245.
5. Guinebretiere JM, Menet E, Tardivon A, Cherel P, Vanel D. Normal and pathological breast, the histological basis. Eur J Radiol 2005, 54 : 6 14.
6. Wang HT, Ma FL, Ma XB, Han RF, Zhang YB, Chang JW. Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH. Cancer Biol Ther 2006, 5 : 104 110.
7. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29 : e45.
8. Bustin SA. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 2002, 29 : 23 39.
9. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999, 68 : 965 1014.
10. Stoesz SP, Friedl A, Haag JD, Lindstrom MJ, Clark GM, Gould MN. Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer 1998, 79 : 565 572.
11. Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res 2005, 65 : 2516 2519.
12. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev1 07 in tumor cell lines and experimental tumors. J Cell Biol 1997, 136 : 935 944.
13. Andreu P, Colnot S, Godard C, Laurent-Puig P, Lamarque D, Kahn A, Perret C et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 2006, 66 : 1949 1955.
14. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3 : 237 252.
15. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv Cancer Res 2005, 94 : 29 86.
16. Woodgett JR. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005, 17 : 150 157.
17. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999, 13 : 2905 2927.
18. Scheid MP, Woodgett JR. PKB/AKT: Functional insights from genetic models. Nat Rev Mol Cell Biol 2001, 2 : 760 768.
19. Delord JP, Allal C, Canal M, Mery E, Rochaix P, Hennebelle I, Pradines A et al. Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma. Ann Oncol 2005, 16 : 1889 1897.
20. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296 : 1655 1657.
21. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002, 99 : 6967 6972.
22. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100 : 8418 8423.
23. Cheng JM, Ding M, Aribi A, Shah P, Rao K. Loss of RAB25 expression in breast cancer. Int J Cancer 2006, 118 : 2957 2964.
24. Osawa Y, Nagaki M, Banno Y, Brenner DA, Nozawa Y, Moriwaki H, Nakashima S. Expression of the NF-κB target gene X-ray-inducible immediate early response factor-1 short enhances TNF-α-induced hepatocyte apoptosis by inhibiting Akt activation. J Immunol 2003, 170 : 4053 4060.
25. Rocher G, Letourneux C, Lenormand P, Porteu F. Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 2007, 282 : 5468 5477.
26. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007, 67 : 167 77.
27. Hajnal A, Klemenz R, Schafer R. Subtraction cloning of H-rev 107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene 1994, 9 : 479 490.
28. Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R. Transcriptional and translational downregulation of H-REV107, a class II tumor suppressor gene located on human chromosome 11q11-12. Oncogene 1998, 17 : 1305 1312.
29. Komatsu M, Chiba T, Tatsumi K, Iemura S, Tanida I, Okazaki N, Ueno T et al. A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J 2004, 23 : 1977 1986.